SCHEMBL4229176

SCHEMBL4229176

CCCCN1CCC(Oc2ccc(C(=O)N(CC(C)OC)c3ccc(Oc4ccc(NC(=O)NC(CC)CC)cc4OC)cc3)cc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MCHR1 Q99705 3/20 0.37
CTSD P07339 2/20 0.36
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
PTGIR P43119 1/20 0.35
PKM P14618 1/20 0.35
TAS1R3 Q7RTX0 1/20 0.34
TAS1R1 Q7RTX1 1/20 0.34
SLC5A7 Q9GZV3 1/20 0.34
MCHR2 Q969V1 1/20 0.34
FGFR1 P11362 4/20 0.34
HTR4 Q13639 1/20 0.34
HRH3 Q9Y5N1 2/20 0.34
CCR3 P51677 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4226786 0.95 SMN1; SMN2 (0.42) SMN1; SMN2NPSR1MCHR1CTSDMEN1
SCHEMBL4237691 0.93 SMN1; SMN2 (0.43) SMN1; SMN2NPSR1MCHR1CTSDMEN1
SCHEMBL13699144 0.92 SMN1; SMN2 (0.43) SMN1; SMN2NPSR1MCHR1CTSDMEN1
SCHEMBL4229165 0.91 SMN1; SMN2 (0.42) SMN1; SMN2NPSR1MCHR1CTSDMEN1
SCHEMBL4228512 0.90 SMN1; SMN2 (0.41) SMN1; SMN2NPSR1MCHR1MEN1GAA
SCHEMBL4226836 0.90 SMN1; SMN2 (0.41) SMN1; SMN2NPSR1MCHR1CTSDMEN1
SCHEMBL4242234 0.90 SMN1; SMN2 (0.41) SMN1; SMN2NPSR1MCHR1MEN1GAA
SCHEMBL4240227 0.89 SMN1; SMN2 (0.39) SMN1; SMN2NPSR1MCHR1CTSDMEN1
SCHEMBL4236543 0.89 SMN1; SMN2 (0.40) SMN1; SMN2NPSR1MCHR1CTSDMEN1
SCHEMBL4236981 0.89 SMN1; SMN2 (0.40) SMN1; SMN2NPSR1MCHR1MEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US claimed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP claimed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO claimed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R SMN1; SMN2 1538/4885NPSR1 12/4885MCHR1 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.